FindTrial
Sign In

Effect of botulinum toxin on Raynaud's phenomenon in patients with systemic sclerosis

Effect of botulinum toxin on Raynaud's phenomenon in patients with systemic sclerosis - BTX on Raynaud's phenomenon in SSc

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000019985
Enrollment
40
Registered
2015-12-16
Start date
2015-12-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Raynaud&#39

Interventions

No treatment Low dose of botulinum toxin injection Medium dose of botulinum toxin injection High dose of botulinum toxin injection

Sponsors

Gunma University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients fulfilled the criteria of SSc proposed by the American College of Rheumatology and the American College of Rheumatology/European League Against Rheumatism classification criteria.

Exclusion criteria

Exclusion criteria: Patients under the age 18, with the pregnancy or having the past medical histories with BTX were excluded.

Design outcomes

Primary

MeasureTime frame
The change in severity of RP, including the frequency, pain, color and duration, by the Raynaud score and VAS at 4 weeks after treatment compared with the baseline.—

Countries

Japan

Contacts

Public ContactSei-ichiro Motegi

Gunma University Graduate School of Medicine Department of Dermatology

smotegi@gunma-u.ac.jp027-220-8284

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026